For decades, men with sexual dysfunction have had access to multiple medications to help improve their sexual performance. Now, a new drug developed specifically to boost female libido is one step closer to being released on the market.

What is the New Female Libido-Boosting Drug?

The new drug is called bremelanotide and is designed to help women with low sexual desire. It is a nasal spray that works by activating the melanocortin receptors in the brain, which are responsible for regulating sexual arousal and desire.

In clinical trials, the drug has shown promising results in increasing sexual desire and improving overall sexual satisfaction in women.

It is still undergoing testing and will require approval from regulatory agencies before being made available to the public.

How Does Bremelanotide Work?

Bremelanotide works by activating the melanocortin receptors in the brain, which are responsible for regulating sexual arousal and desire.

It works differently than Viagra, which targets blood flow to the genitals, by targeting the brain chemistry responsible for sexual arousal.

The drug is administered via a nasal spray, and should be taken approximately 45 minutes before engaging in sexual activity. It should not be used more than once in a 24-hour period.

Who Can Benefit From This Drug?

Bremelanotide is designed for women who have low sexual desire, also known as hypoactive sexual desire disorder (HSDD).

HSDD affects approximately 10% of women, and is characterized by a persistent lack of interest in sexual activity, which may cause significant distress or interpersonal difficulties.

The drug may also benefit women who experience sexual dysfunction as a result of menopause, chemotherapy, or other medical conditions.

Related Article FDA Approves Women’s Viagra for Release in One Year

When Will Bremelanotide Be Available?

Bremelanotide is currently undergoing clinical trials, and is expected to receive approval from the FDA in the near future. Once the drug is approved, it will be available by prescription only.

It is estimated that the drug will be available on the market within the next year, pending regulatory approval.

What Are the Potential Side Effects?

As with any medication, there are potential side effects associated with bremelanotide. The most common side effects reported in clinical trials include nausea, flushing, headache, and injection-site reactions.

It is important to discuss any potential side effects with your healthcare provider before using the medication.

What Are the Alternatives?

In addition to bremelanotide, there are other options available for women experiencing low sexual desire.

These include counseling or therapy to address underlying emotional or psychological issues, lifestyle changes such as exercise or diet modifications, and alternative therapies such as acupuncture or herbal supplements.

However, for some women, these treatments may not be effective, and medication may be necessary to address the problem. Bremelanotide offers a new option for women who have not experienced relief with other treatments.

Conclusion

The development of bremelanotide represents an important advancement in the treatment of female sexual dysfunction, particularly for women with hypoactive sexual desire disorder.

While the drug is not yet available on the market, it offers hope for women experiencing sexual dysfunction and may provide a new treatment option for those who have not benefited from other therapies.

It is important for women to discuss any concerns or questions they may have about their sexual health with their healthcare provider and to explore all available options for treatment.